Mutations of epidermal growth factor receptors play a pivotal role in different cancers [18], and several drugs are already approved for specific subsets of malignancies, i.e., EGFR-mutated non-small cell lung cancer [19] and colorectal cancer [20]. Here, EGFR is linked to non-small cell lung carcinoma.